Fastin

Caloric Restriction, Obesity, Type 2 Diabetes + 6 more
Treatment
3 FDA approvals
20 Active Studies for Fastin

What is Fastin

PhentermineThe Generic name of this drug
Treatment SummaryPhentermine is a drug used to control weight, and it was first introduced in 1959. It is related to, but not as strong as amphetamines and is classified as a Schedule IV drug, meaning it has a low potential for abuse. Phentermine was initially available as part of a combination drug with other medications, but later it was approved on its own. In 2012, a new combination of phentermine with topiramate was approved, which requires lower doses of phentermine to be effective.
Ionaminis the brand name
image of different drug pills on a surface
Fastin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ionamin
Phentermine
1959
298

Approved as Treatment by the FDA

Phentermine, also known as Ionamin, is approved by the FDA for 3 uses including Obesity and Comorbidity .
Obesity
Used to treat Obesity in combination with Topiramate
Comorbidity
Used to treat one related comorbidity in combination with Topiramate
Regime of weight reduction

Effectiveness

How Fastin Affects PatientsPhentermine works by suppressing appetite and increasing the amount of energy the body uses while resting. Clinical studies show that people taking phentermine lose an average of 3.6 kilograms in 2-24 weeks compared to those taking a placebo. Even after treatment ends, patients tend to keep the weight off. Phentermine is related to amphetamines, but does not have any of the same stimulating or dangerous effects, like high blood pressure or an irregular heartbeat.
How Fastin works in the bodyPhentermine works by increasing the amount of a chemical called noradrenaline in the brain. Noradrenaline is a kind of hormone that triggers a “fight or flight” response, which suppresses the feeling of hunger and reduces the need for energy. It also has an indirect effect on serotonin, another hormone that helps regulate appetite. Additionally, it is thought that phentermine may inhibit a chemical called neuropeptide Y, which is involved in hunger signals. Finally, it is a weak inhibitor of monoamine oxidase, which may contribute to its effects.

When to interrupt dosage

The recommended dosage of Fastin hinges on the diagnosed circumstance, including Regime of weight reduction, Hyperlipidemia and Type 2 Diabetes. The measure of dosage is contingent upon the technique of administration (e.g. Oral or Tablet) mentioned in the table underneath.
Condition
Dosage
Administration
Obesity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Caloric Restriction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Type 2 Diabetes
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Hypertensive disease
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
High Cholesterol
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Regime of weight reduction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Chronic Weight Management therapy
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
increase in physical activity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Comorbidity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Warnings

Fastin Contraindications
Condition
Risk Level
Notes
Hyperthyroidism
Do Not Combine
concomitant use or 14 days after discontinuation
Do Not Combine
Agitation
Do Not Combine
Drug abuse
Do Not Combine
Cardiovascular Diseases
Do Not Combine
Open-angle glaucoma
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Phentermine may interact with Pulse Frequency
There are 20 known major drug interactions with Fastin.
Common Fastin Drug Interactions
Drug Name
Risk Level
Description
Iobenguane
Major
Phentermine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylene blue
Major
Phentermine may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Phentermine may increase the serotonergic activities of Mirtazapine.
1-benzylimidazole
Minor
The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Phentermine.
4-Methoxyamphetamine
Minor
The risk or severity of hypertension can be increased when Phentermine is combined with 4-Methoxyamphetamine.
Fastin Toxicity & Overdose RiskThe toxic dose of phentermine in rats is reported to be 151 mg/kg. Overdosing on this drug can cause restlessness, tremors, confusion, hallucinations, fatigue, depression, fast heartbeat, arrhythmias, high or low blood pressure, nausea, vomiting, diarrhea, abdominal cramps, skin problems, insomnia, irritability, hyperactivity, and changes in personality. In severe cases, this can lead to a psychosis-like state. Studies have not been done to determine if phentermine causes cancer or mutations.
image of a doctor in a lab doing drug, clinical research

Fastin Novel Uses: Which Conditions Have a Clinical Trial Featuring Fastin?

104 active clinical trials are currently being conducted to assess the value of Fastin in the management of Type 2 Diabetes, Weight Loss Regime and Disease.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
96 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Obesity
0 Actively Recruiting
Hypertensive disease
0 Actively Recruiting
Comorbidity
0 Actively Recruiting
High Cholesterol
17 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Early Phase 1
Caloric Restriction
0 Actively Recruiting
Regime of weight reduction
0 Actively Recruiting
increase in physical activity
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting

Fastin Reviews: What are patients saying about Fastin?

5Patient Review
6/6/2010
Fastin for Overweight
I had way more energy and didn't crave food as much. I lost 36 pounds in 3 months, but gained it all back after stopping the treatment. It's really effective, but made me dizzy and not want to eat at first.
5Patient Review
6/17/2011
Fastin for Overweight
I do not recommend this drug, especially for those who are under the age of 18. I experienced an abnormal heart rate, shakes, and hallucinations.
5Patient Review
9/1/2010
Fastin for Overweight
I initially lost 75 pounds and have been able to keep off 60 of those pounds for over a year now.
5Patient Review
2/23/2011
Fastin for Overweight
This treatment has helped me a lot. I feel much more motivated and clearheaded now.
5Patient Review
8/9/2009
Fastin for Overweight
5Patient Review
9/10/2009
Fastin for Overweight
5Patient Review
9/10/2009
Fastin for Overweight
5Patient Review
10/15/2009
Fastin for Overweight
4.7Patient Review
12/17/2009
Fastin for Overweight
I have been on fasten for two weeks- already lost 8 pounds with no noticeable side effects (just a little dry mouth, but that's easy to fix with water). This drug is wonderful- my goal is to lose 50 pounds and I'm confident that I'll reach it. I also used to have CFS but not anymore! I can stay awake to watch a movie now, which makes me so happy.
4.7Patient Review
2/13/2010
Fastin for Overweight
I started taking this medication at the end of August and have since lost 30 pounds. I've been feeling really energetic and motivated to exercise, which has been great!
4.3Patient Review
6/22/2011
Fastin for Overweight
I haven't been taking this pill every day as recommended because I get really hungry when I do. Even just taking it 2-3 days in a row makes me ravenous. There are no side effects that I've noticed, which is great, but the hunger is hard to manage. So far I've only been taking it 3 days a week and eating fruit during the day, plus a meal when I get home. In three weeks I've lost at least 8lbs. Does anyone have any suggestions or know if it would work better if taken everyday?
4Patient Review
8/6/2009
Fastin for Overweight
3.7Patient Review
11/17/2011
Fastin for Overweight
This medication was effective in reducing my appetite. However, I also experienced an embarrassing side effect that I have not seen listed anywhere else: an inability to urinate. This happened regardless of how much fluids I consumed or how long I waited. If anyone else has had this problem, please let me know.
2.7Patient Review
5/29/2010
Fastin for Overweight
I saw the best results when I remembered to take this medication on an empty stomach, though after a few months the effectiveness decreased. The time-released capsules were especially helpful.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fastin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is phentermine and fastin the same thing?

"Phentermine is an appetite suppressant that is used as a short-term weight loss aid.

The drug Fastin was once a brand name of phentermine, which was manufactured by King Pharmaceuticals. Phentermine is an appetite suppressant that is used to help with short-term weight loss."

Answered by AI

What does fastin mean?

"It is called "diet pills" because it makes dieting easier by suppressing the appetite.

Amphetamines and other psychoactive drugs that help with weight loss by suppressing appetite are colloquially known as "diet pills.""

Answered by AI

What are fastin pills?

"An prescription medication, Fastin, is available to help treat Obesity. Fastin can be used by itself or in combination with other drugs. Classified as a CNS Stimulant, Anorexiant, and Stimulant, Fastin works by affecting the levels of certain neurotransmitters in the brain."

Answered by AI

Is the drug fastin still available?

"Fastin, a brand name drug, is no longer available in the United States. The generic version of the drug is still available, however."

Answered by AI

Clinical Trials for Fastin

Image of Lipid Clinic at Brown University Health in Providence, United States.

2-HOBA Supplementation for High Cholesterol

18 - 69
All Sexes
Providence, RI
The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels. The main questions it aims to answer are: Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood? Participants will: Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers
Waitlist Available
Has No Placebo
Lipid Clinic at Brown University HealthWenliang Song, MD
Have you considered Fastin clinical trials? We made a collection of clinical trials featuring Fastin, we think they might fit your search criteria.Go to Trials
Image of Sidney & Lois Eskenazi Hospital in Indianapolis, United States.

Composite Intervention for Metabolic Syndrome

18+
All Sexes
Indianapolis, IN
The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility. Participants (n=20) will be randomized to intervention or control (usual care). The composite intervention will include an educational video outlining the adverse effects of MetS and the benefit of walking, a written exercise prescription with a defined goal of walking 150 minutes per week, a Fitbit accelerometer device, resources for healthy eating practices, periodic text message reminders, and an urgent referral to primary care and our health system's Healthy Me clinic for follow-up visit. Investigators hypothesize that this approach will change patient understanding and motivation to increase physical activity and healthy eating habits.
Recruiting
Has No Placebo
Sidney & Lois Eskenazi Hospital
Image of Duke University Medical Center in Durham, United States.

Cardiometabolic Prevention Clinic for Cardiovascular Disease

18+
All Sexes
Durham, NC
This project is studying whether a team-based specialty clinic can help people with type 2 diabetes and heart disease better manage their blood pressure and cholesterol. The clinic includes coordinated care from heart doctors, kidney doctors, diabetes specialists, and liver doctors. The study will compare two groups of patients: one receiving usual care from their primary care provider, and one referred to the Duke Cardiometabolic Prevention Clinic for multidisciplinary care. The main goals are to find out if this clinic improves blood pressure and cholesterol control over 12 months, increases use of recommended heart medications, and reduces hospital visits and other healthcare use. Participants will be randomly assigned to one of the two groups. Those referred to the clinic will: 1) Meet with a cardiologist for an initial evaluation. 2) Be referred to other specialists (such as endocrinology, nephrology, or hepatology) based on their needs. 3) Receive ongoing, coordinated care from a team of specialists working together to improve their heart and metabolic health.
Recruiting
Has No Placebo
Duke University Medical CenterNeha J Pagidipati, MD, MPH
Have you considered Fastin clinical trials? We made a collection of clinical trials featuring Fastin, we think they might fit your search criteria.Go to Trials
Image of Pennington Biomedical Research Center in Baton Rouge, United States.

Continuous Glucose Monitoring for Diabetes

20 - 60
All Sexes
Baton Rouge, LA
Diabetes represents a significant global health burden, with its prevalence continuously rising and causing extensive impacts on individuals, healthcare systems, and society. The International Diabetes Federation (IDF) Diabetes Atlas 2021 reported a global prevalence of 10.5%, with type 2 diabetes (T2D) comprising approximately 90% of cases. In the US, diabetes prevalence stands at 11.6%, affecting roughly 38.4 million adults, with approximately 1.2 million new diagnoses each year. Obesity, affecting over 42% of US adults-including 9.4% with severe obesity-is recognized as the primary risk factor for diabetes. Severe obesity, present in around 30% of T2D patients, markedly elevates the risk for cardiovascular disease, non-alcoholic fatty liver disease, and other comorbidities, resulting in increased mortality rates. Addressing this burden requires coordinated strategies targeting prevention, early diagnosis, effective treatment, and patient education. However, conventional management methods, such as lifestyle modifications and pharmacotherapy, often result in transient weight loss and temporary diabetes remission, with frequent relapses. In contrast, metabolic surgery, notably Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG), has emerged as a highly effective intervention for significant weight loss and durable diabetes remission, particularly among patients with severe obesity and T2D. These procedures improve metabolic outcomes beyond weight reduction, enhancing insulin sensitivity and glycemic control. Consequently, integrating metabolic surgery into standard diabetes care guidelines and expanding patient access is crucial. Although metabolic surgery outperforms intensive medical therapy, traditional assessment methods, such as HbA1c, have notable limitations. HbA1c measures average glucose levels without capturing short-term fluctuations, glucose variability, or hypoglycemia, limiting its utility post-surgery. Continuous glucose monitoring (CGM) offers real-time, detailed insights into glucose patterns, variability, postprandial excursions, and hypoglycemia, making it highly suitable for postoperative monitoring. CGM provides a clearer picture of immediate and long-term metabolic changes following surgery, allowing early identification of abnormal glycemic patterns influenced by surgical alterations in gastrointestinal anatomy and diet. It enables the detection of post-bariatric hypoglycemia (PBH), a recognized complication following metabolic surgery, and improves understanding of hypoglycemia unawareness-critical for enhancing patient safety and clinical outcomes. However, current research on CGM in metabolic surgery remains limited, primarily consisting of cross-sectional or retrospective studies with small sample sizes, lacking preoperative data, and employing short monitoring periods. Therefore, robust studies such as randomized controlled trials (RCTs) are essential to validate CGM's efficacy and inform its broader adoption in clinical practice.
Waitlist Available
Has No Placebo
Pennington Biomedical Research Center
Image of UNC Lineberger Comprehensive Cancer Center in Chapel Hill, United States.

Support Program for Caregivers of Patients with Cancer and Diabetes

18 - 99
All Sexes
Chapel Hill, NC
This study investigates the feasibility, acceptability, and preliminary efficacy of enCompass Humana, a social support intervention for caregivers of patients with cancer and diabetes. The enCompass program aims to improve support for these caregivers through a randomized feasibility study of a pilot-tested coaching and navigation program. Caregiver services and system-level support are essential, but successful interventions for cancer caregivers are rarely standardized or systematically disseminated. Consequently, many programs do not reach the most underserved caregivers. Challenges to implementation include substantial clinical staff involvement, lack of dissemination and implementation information, and failure to tailor interventions to rural contexts. Despite the lack of standardized supportive interventions, national reports and legislative efforts increasingly recognize the need to support caregivers. Caregivers reported unmet needs in all domains of social support, including instrumental help (e.g., in-home help, housekeeping), logistical and coordination support (e.g., food delivery, accompanying patients to appointments), information about illness and progression, emotional support, self-care guidance, and financial assistance (e.g., parking costs, lost wages). Caregivers show high interest in services but cited uncertainty and lack of strategies for accessing resources. Many are unaware of existing services. Interviews with oncology clinicians and healthcare administrators revealed similar findings: resources exist, but there is no system to match them with caregivers' needs. Preliminary data suggest the intervention improves caregiver coping self-efficacy and reduces anxiety and depression in patients. With input from stakeholders, including caregivers, patients, family caregiving experts, and clinical care experts, the study team adapted the CARING application into enCompass to mitigate structural barriers and normalize support-seeking. The long-term goal is to adapt this psychosocial support program to increase self-efficacy, support-seeking, and reduce loneliness among caregivers. It is hypothesized that enCompass will build self-efficacy and coping skills, serving caregivers throughout the patient's illness and complications.
Recruiting
Has No Placebo
UNC Lineberger Comprehensive Cancer Center (+2 Sites)Erin E Kent, PhD
Have you considered Fastin clinical trials? We made a collection of clinical trials featuring Fastin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security